Vericel Corporation

44.45
-1.62 (-3.52%)
At close: Mar 28, 2025, 3:59 PM
42.57
-4.23%
After-hours: Mar 28, 2025, 04:27 PM EDT

Company Description

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States.

The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.

Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

The company was formerly known as Aastrom Biosciences, Inc.

Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Vericel Corporation
Vericel Corporation logo
Country United States
IPO Date Feb 4, 1997
Industry Biotechnology
Sector Healthcare
Employees 357
CEO Dominick C. Colangelo Esq.

Contact Details

Address:
64 Sidney Street
Cambridge, Massachusetts
United States
Website https://vcel.com

Stock Details

Ticker Symbol VCEL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000887359
CUSIP Number 92346J108
ISIN Number US92346J1088
Employer ID 94-3096597
SIC Code 2836

Key Executives

Name Position
Dominick C. Colangelo Esq. Chief Executive Officer, President & Director
Joseph Anthony Mara Jr. Chief Financial Officer & Treasurer
Michael Halpin Chief Operating Officer
Sean C. Flynn Chief Legal Officer
Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. Chief Medical Officer
Eric Burns Vice President of Finance & Investor Relations
Jonathan D. Siegal Principal Accounting Officer, Vice President & Corporate Controller
Karen Mahoney Chief Human Resources Officer
Patrick Helfrich Vice President of Marketing & Commercial Strategy
Patrick J. Fowler Senior Vice President of Corporate Development & Strategy

Latest SEC Filings

Date Type Title
Mar 20, 2025 DEFA14A Filing
Mar 20, 2025 DEF 14A Filing
Mar 20, 2025 ARS Filing
Mar 14, 2025 4 Filing
Mar 05, 2025 4 Filing
Mar 05, 2025 4 Filing
Mar 05, 2025 4 Filing
Mar 05, 2025 4 Filing
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report